Patents by Inventor Jochen Deckert

Jochen Deckert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
    Publication number: 20260053941
    Abstract: Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes comprising an oligonucleotide (e.g., an RNAi oligonucleotide such as an siRNA, useful for targeting DUX4) covalently linked to an antibody (e.g., anti-TfR1 antibody).
    Type: Application
    Filed: November 7, 2025
    Publication date: February 26, 2026
    Applicant: Dyne Therapeutics, Inc.
    Inventors: Timothy Weeden, Nelson Hsia, Stefano Zanotti, Oxana Beskrovnaya, Qifeng Qiu, Scott Hilderbrand, Jochen Deckert, Hans-Peter Vornlocher, Markus Hossbach, Kathrin Hultsch, Nicholas C. Yoder, Benjamin Vieira
  • COMPOSITIONS AND METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    Publication number: 20250146000
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Application
    Filed: September 13, 2024
    Publication date: May 8, 2025
    Inventors: Dinah Wen-Yee SAH, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert
  • COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE
    Publication number: 20240415868
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the HTT gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating Huntington's Disease (HD) using the siRNA molecules and AAV vectors.
    Type: Application
    Filed: February 29, 2024
    Publication date: December 19, 2024
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Pengcheng Zhou, Xin Wang, Jochen Deckert, Markus Hossbach
  • Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
    Patent number: 12123002
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Grant
    Filed: December 20, 2022
    Date of Patent: October 22, 2024
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert
  • COMPOSITIONS AND METHODS OF TREATING HUNTINGTON'S DISEASE
    Publication number: 20240226203
    Abstract: The present invention relates to adeno-associated viral (AAV) particles encoding siRNA molecules and methods for treating Huntington's Disease (HD).
    Type: Application
    Filed: July 13, 2023
    Publication date: July 11, 2024
    Inventors: Dinah Wen-Yee Sah, Fen Chen, Pengcheng Zhou, Xin Wang, Yanqun Shu, Jinzhao Hou, Jochen Deckert, Markus Hossbach
  • COMPOSITIONS AND METHODS OF TREATING HUNTINGTON'S DISEASE
    Publication number: 20240131093
    Abstract: The present invention relates to adeno-associated viral (AAV) particles encoding siRNA molecules and methods for treating Huntington's Disease (HD).
    Type: Application
    Filed: July 12, 2023
    Publication date: April 25, 2024
    Inventors: Dinah Wen-Yee Sah, Fen Chen, Pengcheng Zhou, Xin Wang, Yanqun Shu, Jinzhao Hou, Jochen Deckert, Markus Hossbach
  • Compositions and methods for treating Huntington's disease
    Patent number: 11951121
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the HTT gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating Huntington's Disease (HD) using the siRNA molecules and AAV vectors.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: April 9, 2024
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Pengcheng Zhou, Xin Wang, Jochen Deckert, Markus Hossbach
  • COMPOSITIONS AND METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    Publication number: 20230332156
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Application
    Filed: December 20, 2022
    Publication date: October 19, 2023
    Inventors: Dinah Wen-Yee SAH, Jinzhao HOU, Mathieu E. NONNENMACHER, Pengcheng ZHOU, Markus HOSSBACH, Jochen DECKERT
  • Compositions and methods of treating Huntington's disease
    Patent number: 11752181
    Abstract: The present invention relates to adeno-associated viral (AAV) particles encoding siRNA molecules and methods for treating Huntington's Disease (HD).
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: September 12, 2023
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Dinah Wen-Yee Sah, Fen Chen, Pengcheng Zhou, Xin Wang, Yanqun Shu, Jinzhao Hou, Jochen Deckert, Markus Hossbach
  • Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
    Patent number: 11542506
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: January 3, 2023
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert
  • COMPOSITIONS AND METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    Publication number: 20210139915
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Application
    Filed: January 6, 2021
    Publication date: May 13, 2021
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert
  • Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
    Patent number: 10920227
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: February 16, 2021
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert
  • COMPOSITIONS AND METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    Publication number: 20200157547
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Application
    Filed: January 28, 2020
    Publication date: May 21, 2020
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert
  • Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
    Patent number: 10597660
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 24, 2020
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert
  • COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE
    Publication number: 20190160091
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the HTT gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating Huntington's Disease (HD) using the siRNA molecules and AAV vectors.
    Type: Application
    Filed: May 18, 2017
    Publication date: May 30, 2019
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Pengcheng Zhou, Xin Wang, Jochen Deckert, Markus Hossbach
  • COMPOSITIONS AND METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    Publication number: 20180282732
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Application
    Filed: November 13, 2015
    Publication date: October 4, 2018
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert
  • RNA TARGETED TO C-MET
    Publication number: 20150337318
    Abstract: A double stranded RNA (dsRNA) molecule targeted to MET includes a duplex region having a sense region and an antisense region at least substantially complementary to the sense region. The sense region and the antisense region each have between 18 and 30 nucleotides. The antisense region includes a nucleotide sequence that is fully complementary to at least 15 contiguous nucleotides of any one of SEQ ID NOs: 1-26.
    Type: Application
    Filed: February 19, 2013
    Publication date: November 26, 2015
    Inventors: Markus HOSSBACH, Jochen DECKERT
  • RNA TARGETED TO BETA CATENIN
    Publication number: 20150291956
    Abstract: A double stranded RNA (dsRNA) molecule targeted to beta catenin includes a duplex region having a sense region and an antisense region at least substantially complementary to the sense region. The sense region and the antisense region each have between 18 and 30 nucleotides. The antisense region includes a nucleotide sequence that is fully complementary to at least 15 contiguous nucleotides of any one of SEQ ID NOs: 1-24.
    Type: Application
    Filed: February 19, 2013
    Publication date: October 15, 2015
    Applicant: PHASERX, INC.
    Inventors: Markus Hossbach, Jochen Deckert
  • Compositions and methods for inhibiting gene expression of hepatitis B virus
    Patent number: 8809293
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a Hepatitis B Virus gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Hepatitis B Virus infection using said pharmaceutical composition; and methods for inhibiting the expression of a Hepatitis B Virus gene in a cell.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: August 19, 2014
    Assignee: Arrowhead Madison Inc.
    Inventors: Daniel Chin, Jochen Deckert, Markus Hossbach, Matthias John
  • Compositions and methods for inhibiting gene expression of hepatitis B virus
    Patent number: RE48345
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a Hepatitis B Virus gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Hepatitis B Virus infection using said pharmaceutical composition; and methods for inhibiting the expression of a Hepatitis B Virus gene in a cell.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: December 8, 2020
    Assignee: Arrowhead Pharmaceuticals Inc.
    Inventors: Daniel J. Chin, Jochen Deckert, Markus Hossbach, Matthias John